NO964199L - Treatment of autoimmune disease using oral tolerance and / or type I interferon - Google Patents

Treatment of autoimmune disease using oral tolerance and / or type I interferon

Info

Publication number
NO964199L
NO964199L NO964199A NO964199A NO964199L NO 964199 L NO964199 L NO 964199L NO 964199 A NO964199 A NO 964199A NO 964199 A NO964199 A NO 964199A NO 964199 L NO964199 L NO 964199L
Authority
NO
Norway
Prior art keywords
type
interferon
treatment
oral tolerance
autoimmune disease
Prior art date
Application number
NO964199A
Other languages
Norwegian (no)
Other versions
NO964199D0 (en
Inventor
David A Hafler
Howard L Weiner
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of NO964199D0 publication Critical patent/NO964199D0/en
Publication of NO964199L publication Critical patent/NO964199L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)

Abstract

Fremgangsmåte for behandling av autoimmune sykdommer så som multippel sklerose ved oral administrering av et tilstedeværende antigen så som myelinbasisk protein eller proteolipid protein sammen med et polypeptid som har type I interferon aktivitet på en slik måte at det induserer oral toleranse til det tilstedeværende antigenet som resulterer i suppresjon av den autoimmune responsen.A method of treating autoimmune diseases such as multiple sclerosis by oral administration of an antigen present such as myelin basic protein or proteolipid protein together with a polypeptide having type I interferon activity in such a way that it induces oral tolerance to the antigen present which results in suppression of the autoimmune response.

NO964199A 1994-04-08 1996-10-03 Treatment of autoimmune disease using oral tolerance and / or type I interferon NO964199L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22537294A 1994-04-08 1994-04-08
PCT/US1995/004120 WO1995027499A1 (en) 1994-04-08 1995-04-07 Treatment of autoimmune disease using oral tolerization and/or type i interferon

Publications (2)

Publication Number Publication Date
NO964199D0 NO964199D0 (en) 1996-10-03
NO964199L true NO964199L (en) 1996-10-03

Family

ID=22844605

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964199A NO964199L (en) 1994-04-08 1996-10-03 Treatment of autoimmune disease using oral tolerance and / or type I interferon

Country Status (9)

Country Link
EP (1) EP0752880A4 (en)
JP (1) JPH09511745A (en)
AU (1) AU686797B2 (en)
BR (1) BR9507451A (en)
CA (1) CA2185353A1 (en)
HU (1) HUT74900A (en)
IL (1) IL113303A0 (en)
NO (1) NO964199L (en)
WO (1) WO1995027499A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US6372206B1 (en) 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
IL115766A0 (en) * 1994-10-25 1996-01-19 Immulogic Pharma Corp Composition and treatment for multiple sclerosis
NZ336548A (en) * 1996-12-24 2001-09-28 Biogen Inc Stable liquid interferon formulations comprising an amino acid as the stabilising agent
CA2252790A1 (en) * 1997-02-28 1998-09-03 Enzo Therapeutics, Inc. Novel processes implementing selective immune down regulation (sidr)
DK2011514T3 (en) 1997-03-21 2012-03-26 Chugai Pharmaceutical Co Ltd Preventive or therapeutic agent for sensitized T cell mediated diseases comprising IL-6 antagonist as an active ingredient
WO2001068124A2 (en) 2000-03-15 2001-09-20 The Brigham And Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
CA2410563C (en) 2000-05-24 2013-04-23 John M. Hallenbeck Methods for preventing strokes by inducing tolerance to e-selectin
EP1582216A4 (en) 2002-12-26 2010-04-21 Asubio Pharma Co Ltd Remedy for pemphigoid
US8920808B2 (en) 2006-10-31 2014-12-30 East Carolina University Cytokine-based fusion proteins for treatment of multiple sclerosis
EP3348275A3 (en) * 2009-03-31 2018-10-24 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
JP6590330B2 (en) * 2013-11-11 2019-10-16 キッコーマン株式会社 Oral immune tolerance enhancing substance screening method and oral immune tolerance enhancing composition
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2844889A (en) * 1988-01-22 1989-07-27 Collagen Corporation Method for suppressing the growth of normal and cancer cells
KR950700082A (en) * 1992-02-28 1995-01-16 로버트 씨. 비숍 How to Treat Autoimmune Diseases by Bystander

Also Published As

Publication number Publication date
AU2277695A (en) 1995-10-30
CA2185353A1 (en) 1995-10-19
EP0752880A4 (en) 2000-08-09
HUT74900A (en) 1997-02-28
WO1995027499A1 (en) 1995-10-19
JPH09511745A (en) 1997-11-25
AU686797B2 (en) 1998-02-12
NO964199D0 (en) 1996-10-03
BR9507451A (en) 1997-08-05
IL113303A0 (en) 1995-07-31
HU9602750D0 (en) 1996-11-28
EP0752880A1 (en) 1997-01-15

Similar Documents

Publication Publication Date Title
ATE228373T1 (en) SUPPRESSION OF AUTOIMMUNE DISEASES BY ANTIGENS IN WAITING
DE69133516D1 (en) TREATMENT OF AUTOIMMUNE DISEASES BY ORAL ADMINISTRATION OF AUTO ATIGENIGEN
NO964199L (en) Treatment of autoimmune disease using oral tolerance and / or type I interferon
NO20092874L (en) Prevention and treatment of amyloidogenic disease
ATE219373T1 (en) MEDICATIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES USING INTERFERON-TAU
DE3854741D1 (en) TREATING AUTOIMMUNE DISEASES BY ORAL ADMINISTRATION OF AUTOANTIGENS.
DE69033487D1 (en) TREATING AUTOIMMUNE DISEASES BY ADMINISTRATING AUTOANTIGENS IN THE FORM OF AEROSOL
NO964200L (en) Treatment of autoimmune disease using oral tolerance and / or Th2-enhancing cytokines
ATE204178T1 (en) METHOD FOR TREATING AND PREVENTING TYPE 1 DIABETIS BY ORAL ADMINISTRATION OF INSULIN
EP0726758A4 (en) Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
DE69410254D1 (en) TREATMENT OF MYCOBACTERIAL DISEASES THROUGH THE ADMINISTRATION OF BACRERIAL-KILLING, PLEASURE-INCREASING PROTEIN FRAGMENTS
AU621830B2 (en) Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
ATE234111T1 (en) THERAPEUTIC USES OF BPI PROTEIN PRODUCTS IN PEOPLE WITH BLEEDING CAUSED BY TRAUMA
DE69820053D1 (en) INTERFERENCE NOTOCORD TO REDUCE SYMPTOMS / TREATMENT OF ARTHRITIS
HK1014498A1 (en) Bpi-protein-products for depressed reticuloendothelial system function.
DK0752884T3 (en) Process for the treatment of autoimmune diseases using type 1 interferons
NO982463L (en) Use of a combination of pentoxyphylline and type I interferons for the treatment of multiple sclerosis
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis
EP0642333A4 (en) Method and composition for the treatment of disorders involving immunological dysfunction.
UA6640A (en) Method for prediction of acute condition of associated disease at activation of main pathology

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application